Stock WBIO WPD PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News WPD Pharmaceuticals Inc.

Equities

WBIO

CA92941F1053

Market Closed - Canadian Securities Exchange
Other stock markets
 07:19:31 28/06/2022 pm IST 		5-day change 1st Jan Change
0.045 CAD -.--% Intraday chart for WPD Pharmaceuticals Inc. -.--% -.--%
08/05 WPD Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
05/02 WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
WPD Pharmaceuticals : Announces Filing of Annual Financial Statements and Provides Corporate Update
PU
WPD Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
WPD Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
WPD Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
WPD Pharmaceuticals : Sp. z o. o., received the second tranche of the funds
PU
WPD Pharmaceuticals : Sp. z o. o., received the first tranche of the funds
PU
WPD Pharmaceuticals : Polish Subsidiary Signs Investment Agreement with ACRX Investments Limited
PU
WPD Pharmaceuticals : Announces Closing of Convertible Debenture Private Placement
PU
WPD Pharmaceuticals Inc. announced that it has received CAD 0.3 million in funding
CI
WPD Pharmaceuticals Inc. Provides Update on Research Project Pipeline
CI
WPD Pharmaceuticals Inc. Announces Directorate Appointments
CI
WPD Pharmaceuticals Inc. announced that it expects to receive CAD 0.3 million in funding
CI
WPD Pharmaceuticals Inc. Announces First Adult Patient Dosed in Phase 1B/2 Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
CI
WPD Pharmaceuticals Announces First Two Sites Initiated in Poland in Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy (WPD-201)
CI
WPD Pharmaceuticals Inc. Announces First Patient Dosed in Phase 1B/2 Clinical Trial of Annamycin
CI
Liam Corcoran Resigns from WPD Pharmaceuticals Inc.'s Board of Directors, Effective December 1, 2022
CI
WPD Pharmaceuticals : Provides a Corporate Update
PU
WPD Pharmaceuticals Inc. announced that it expects to receive PLN 1.7 million in funding
CI
IIROC Trading Halt - WBIO
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. WBIO Stock
  4. News WPD Pharmaceuticals Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW